Indegene (INDGN) Stock Overview
Operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for INDGN from our risk checks.
INDGN Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
₹808.94
FV
35.9% undervalued intrinsic discount15.98%
Revenue growth p.a.
212
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
Indegene Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹518.45 |
| 52 Week High | ₹632.90 |
| 52 Week Low | ₹414.00 |
| Beta | 0.76 |
| 1 Month Change | 3.74% |
| 3 Month Change | 9.93% |
| 1 Year Change | -16.34% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 14.70% |
Recent News & Updates
Narrative Update • May 14
INDGN: Upcoming Tax Assessment Outcome Will Support Future Upside
Analysts have raised Indegene's price target from ₹568.57 to ₹592.43, reflecting updated assumptions that include slightly lower discount and revenue growth rates, a marginally higher profit margin, and a modestly lower future P/E multiple. What's in the News The Income Tax Department has issued a final assessment order for Assessment Year 2023-24 with an income tax demand of ₹436.88441 million, following transfer pricing adjustments of ₹1,234.110559 million.Analysis Article • May 10
Investors Can Find Comfort In Indegene's (NSE:INDGN) Earnings Quality
The market was pleased with the recent earnings report from Indegene Limited ( NSE:INDGN ), despite the profit numbers...Narrative Update • Apr 25
INDGN: Upcoming Results Review And Dividend Decision Will Support Future Upside
Indegene's analyst price target has edged down by about ₹3 per share as analysts fine-tune assumptions around the discount rate, profit margin, revenue growth, and future P/E multiples in their updated models. What's in the News A board meeting is scheduled for April 29, 2026, to review and approve the audited consolidated financial results for Indegene and its subsidiaries for the quarter and year ended March 31, 2026, prepared under INDAS, along with the auditor's report (company filing).Narrative Update • Apr 08
INDGN: Upcoming Board Review And RSU Allotment Will Support Future Upside
Analysts now set their price target for Indegene at ₹571.57 versus ₹603.00 earlier. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions.
New Narrative • Apr 04
Gen AI Adoption And Pharma Cost Pressures Will Shape Steady Long Term Outcomes
Catalysts About Indegene Indegene provides technology and AI led services to global life sciences companies across commercial, medical, regulatory and safety operations. What are the underlying business or industry changes driving this perspective?Recent updates
Narrative Update • May 14
INDGN: Upcoming Tax Assessment Outcome Will Support Future Upside
Analysts have raised Indegene's price target from ₹568.57 to ₹592.43, reflecting updated assumptions that include slightly lower discount and revenue growth rates, a marginally higher profit margin, and a modestly lower future P/E multiple. What's in the News The Income Tax Department has issued a final assessment order for Assessment Year 2023-24 with an income tax demand of ₹436.88441 million, following transfer pricing adjustments of ₹1,234.110559 million.Analysis Article • May 10
Investors Can Find Comfort In Indegene's (NSE:INDGN) Earnings Quality
The market was pleased with the recent earnings report from Indegene Limited ( NSE:INDGN ), despite the profit numbers...Narrative Update • Apr 25
INDGN: Upcoming Results Review And Dividend Decision Will Support Future Upside
Indegene's analyst price target has edged down by about ₹3 per share as analysts fine-tune assumptions around the discount rate, profit margin, revenue growth, and future P/E multiples in their updated models. What's in the News A board meeting is scheduled for April 29, 2026, to review and approve the audited consolidated financial results for Indegene and its subsidiaries for the quarter and year ended March 31, 2026, prepared under INDAS, along with the auditor's report (company filing).Narrative Update • Apr 08
INDGN: Upcoming Board Review And RSU Allotment Will Support Future Upside
Analysts now set their price target for Indegene at ₹571.57 versus ₹603.00 earlier. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions.New Narrative • Apr 04
Gen AI Adoption And Pharma Cost Pressures Will Shape Steady Long Term Outcomes
Catalysts About Indegene Indegene provides technology and AI led services to global life sciences companies across commercial, medical, regulatory and safety operations. What are the underlying business or industry changes driving this perspective?Narrative Update • Mar 24
INDGN: Steady Fair Value And Upcoming Board Review Will Support Upside Potential
Analysts have kept Indegene's fair value estimate steady at ₹603.0, with only marginal tweaks to assumptions such as the discount rate and future P/E. This reflects fine tuning of their valuation framework rather than a major shift in view.
New Narrative • Mar 14
Indegene deep undervalued stock
At ₹429–430 levels (near 52-week low), Indegene offers excellent risk-reward for 12–24 month horizon. Explosive long-term growth (35% sales CAGR, 68% profit CAGR), first $100M quarter, near-zero debt, and powerful AI/GenAI positioning in the high-growth life-sciences sector make this a high-quality compounder.Narrative Update • Mar 05
INDGN: Upcoming Board Decisions On RSU Allotment Will Support Continued Positive Momentum
Narrative Update on Indegene Analysts have trimmed their price target for Indegene slightly from about ₹606 to ₹603, reflecting modest tweaks to fair value, discount rate and future P/E assumptions while keeping revenue growth and profit margin expectations effectively unchanged. What's in the News A board meeting is scheduled for January 29, 2026 to review unaudited consolidated financial results for the quarter ended December 31, 2025 under IND AS, along with the auditors' limited review report (Key Developments).Narrative Update • Feb 19
INDGN: Upcoming Board Decisions On RSU Allotment Will Support Continued Positive Momentum
Analysts have kept their fair value estimate for Indegene steady at ₹605.86 per share, with only minor tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding this price target reaffirmation. What's in the News A board meeting is scheduled for January 29, 2026 to review unaudited consolidated financial results for Indegene and its subsidiaries for the quarter ended December 31, 2025, prepared under IND AS, along with the auditors' limited review report (company filing).Narrative Update • Feb 04
INDGN: Upcoming Board And Shareholder Meetings Will Support Continued Positive Momentum
Analysts have trimmed their fair value estimate for Indegene from ₹609.63 to ₹605.86, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News A board meeting is scheduled for January 29, 2026, to review unaudited consolidated financial results for the quarter ended December 31, 2025, under INDAS, along with the auditors' limited review report (company filing).Analysis Article • Feb 02
Earnings Miss: Indegene Limited Missed EPS By 8.1% And Analysts Are Revising Their Forecasts
Last week saw the newest third-quarter earnings release from Indegene Limited ( NSE:INDGN ), an important milestone in...Narrative Update • Jan 08
INDGN: Expanded Consulting Practice And Upcoming Meetings Will Support Continued Positive Momentum
Analysts have trimmed their fair value estimate for Indegene slightly from ₹610.25 to ₹609.63. This reflects updated assumptions on discount rate, revenue growth, profit margin and future P/E that keep the overall valuation view broadly intact.Narrative Update • Dec 23
INDGN: Upcoming Board And Shareholder Actions Will Support Continued Positive Momentum
Narrative Update on Indegene Analysts have slightly reduced their price target on Indegene by approximately ₹2 to about ₹610, reflecting marginal adjustments to discount rate and profit margin assumptions, along with a modest increase in long term revenue growth expectations. What's in the News Indegene has expanded its Consulting Practice to provide integrated strategy and transformation support for life sciences clients, aiming to deliver both strategic insight and hands on implementation across the value chain (Key Developments).Narrative Update • Dec 09
INDGN: Upcoming Board Meeting Will Drive Continued Positive Momentum
Analysts have modestly raised their price target on Indegene by about 1 percent to approximately $612, citing slightly stronger long term revenue growth expectations and a marginally higher future earnings multiple, despite largely stable profit margin and discount rate assumptions. What's in the News Board meeting scheduled on October 30, 2025 to review unaudited consolidated and standalone financial results for the quarter ended September 30, 2025 and consider equity allotments under ESOP 2020 and RSU 2020 schemes (company filing) Expansion of Indegene's Consulting Practice to provide integrated strategy and transformation support for life sciences clients facing large scale, technology driven change across the value chain (company announcement) Strategic partnership with Datavant to integrate its health data network into Indegene's NEXT Patient Recruitment platform, aiming to speed up clinical trial enrollment and improve patient recruitment, particularly in rare diseases (Datavant and company announcement) Valuation Changes The fair value estimate has risen slightly to about ₹612 per share from roughly ₹608 per share, reflecting a modest upward revision.Narrative Update • Nov 25
INDGN: Upcoming Board Meeting and Expansions Will Drive Continued Momentum
Analysts have slightly adjusted their price target for Indegene, lowering it from ₹609.57 to ₹608.14 as a result of modest revisions in growth and profitability assumptions. What's in the News A board meeting is scheduled for October 30, 2025 to consider consolidated and standalone financial results as well as ESOP/RSU allotments (Board Meeting).Narrative Update • Nov 10
INDGN: Rising Revenue and Business Expansion Will Drive Continued Outperformance
Narrative Update on Indegene Price Target Analysts have lowered their price target for Indegene from ₹644.67 to ₹609.57, citing revised expectations on future profitability and growth dynamics. What's in the News Board meeting scheduled for October 30, 2025, to review unaudited consolidated and standalone financial results for the quarter ended September 30, 2025.Analysis Article • Nov 02
Indegene Limited Beat Revenue Forecasts By 5.6%: Here's What Analysts Are Forecasting Next
The quarterly results for Indegene Limited ( NSE:INDGN ) were released last week, making it a good time to revisit its...Analysis Article • Jul 23
Getting In Cheap On Indegene Limited (NSE:INDGN) Is Unlikely
There wouldn't be many who think Indegene Limited's ( NSE:INDGN ) price-to-earnings (or "P/E") ratio of 32.5x is worth...New Narrative • May 11
M&A And Cortex Integration Will Expand Enterprise Opportunities
M&A activities and AI integration signal innovation and efficiency, likely boosting topline growth and improving net margins through cost reductions.Analysis Article • May 03
Indegene Limited (NSE:INDGN) Annual Results: Here's What Analysts Are Forecasting For This Year
Indegene Limited ( NSE:INDGN ) shareholders are probably feeling a little disappointed, since its shares fell 6.3% to...Analysis Article • Feb 25
Indegene Limited's (NSE:INDGN) Price Is Out Of Tune With Earnings
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 26x, you may consider...Shareholder Returns
| INDGN | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 0.2% | -1.7% | 0.4% |
| 1Y | -16.3% | -1.2% | -0.6% |
Return vs Industry: INDGN underperformed the Indian Life Sciences industry which returned -1.2% over the past year.
Return vs Market: INDGN underperformed the Indian Market which returned -0.6% over the past year.
Price Volatility
| INDGN volatility | |
|---|---|
| INDGN Average Weekly Movement | 5.1% |
| Life Sciences Industry Average Movement | 6.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.3% |
| 10% least volatile stocks in IN Market | 4.8% |
Stable Share Price: INDGN has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: INDGN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 4,158 | Manish Gupta | www.indegene.com |
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies.
Indegene Limited Fundamentals Summary
| INDGN fundamental statistics | |
|---|---|
| Market cap | ₹124.43b |
| Earnings (TTM) | ₹4.01b |
| Revenue (TTM) | ₹35.11b |
31.0x
P/E Ratio3.5x
P/S RatioIs INDGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INDGN income statement (TTM) | |
|---|---|
| Revenue | ₹35.11b |
| Cost of Revenue | ₹0 |
| Gross Profit | ₹35.11b |
| Other Expenses | ₹31.09b |
| Earnings | ₹4.01b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 16.71 |
| Gross Margin | 100.00% |
| Net Profit Margin | 11.43% |
| Debt/Equity Ratio | 0% |
How did INDGN perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield13%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/02 20:51 |
| End of Day Share Price | 2026/06/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indegene Limited is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| Deep Shah | 360 ONE Capital Market Private Limited |
| Rajiv Berlia | Citigroup Inc |